Verséa Ophthalmics launches T-POC TOTAL IgE test for enhanced ocular disease diagnosis and treatment
Verséa Ophthalmics announced the commencement of initial shipments of its T-POC TOTAL IgE Immunoassay and Lateral Flow Readers, according to a press release.
The T-POC TOTAL IgE Immunoassay Kit is a newly developed quantitative point-of-care test designed for diagnosing and managing patients with ocular surface disease (OSD). It focuses on measuring Total Immunoglobulin E (IgE), a crucial biomarker associated with allergic conjunctivitis.
Unlike other available clinical assays, this test provides a numerical value of IgE levels, enabling clinicians to differentiate between different eye conditions and make informed prescribing decisions. Moreover, repeating the test after initiating treatment may help confirm a desired therapeutic response.
This initial shipment of the TOTAL IgE testing platform represents the first phase of Verséa Ophthalmics’ efforts, with Phase 2 anticipated to follow in the next few weeks. In Phase 2, they plan to ship the T-POC LACTOFERRIN test, which is used for aqueous deficient DED and can be performed on the same digital reader platform.
Related Content
